FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3090717270> ?p ?o ?g. }

• W3090717270 endingPage "2438" @default.
• W3090717270 startingPage "2427" @default.
• W3090717270 abstract "Testing of vaccine candidates to prevent infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an older population is important, since increased incidences of illness and death from coronavirus disease 2019 (Covid-19) have been associated with an older age.We conducted a phase 1, dose-escalation, open-label trial of a messenger RNA vaccine, mRNA-1273, which encodes the stabilized prefusion SARS-CoV-2 spike protein (S-2P) in healthy adults. The trial was expanded to include 40 older adults, who were stratified according to age (56 to 70 years or ≥71 years). All the participants were assigned sequentially to receive two doses of either 25 μg or 100 μg of vaccine administered 28 days apart.Solicited adverse events were predominantly mild or moderate in severity and most frequently included fatigue, chills, headache, myalgia, and pain at the injection site. Such adverse events were dose-dependent and were more common after the second immunization. Binding-antibody responses increased rapidly after the first immunization. By day 57, among the participants who received the 25-μg dose, the anti-S-2P geometric mean titer (GMT) was 323,945 among those between the ages of 56 and 70 years and 1,128,391 among those who were 71 years of age or older; among the participants who received the 100-μg dose, the GMT in the two age subgroups was 1,183,066 and 3,638,522, respectively. After the second immunization, serum neutralizing activity was detected in all the participants by multiple methods. Binding- and neutralizing-antibody responses appeared to be similar to those previously reported among vaccine recipients between the ages of 18 and 55 years and were above the median of a panel of controls who had donated convalescent serum. The vaccine elicited a strong CD4 cytokine response involving type 1 helper T cells.In this small study involving older adults, adverse events associated with the mRNA-1273 vaccine were mainly mild or moderate. The 100-μg dose induced higher binding- and neutralizing-antibody titers than the 25-μg dose, which supports the use of the 100-μg dose in a phase 3 vaccine trial. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 Study ClinicalTrials.gov number, NCT04283461.)." @default.
• W3090717270 created "2020-10-08" @default.
• W3090717270 creator A5000950209 @default.
• W3090717270 creator A5004205181 @default.
• W3090717270 creator A5005833714 @default.
• W3090717270 creator A5005860294 @default.
• W3090717270 creator A5013550134 @default.
• W3090717270 creator A5014451298 @default.
• W3090717270 creator A5017501496 @default.
• W3090717270 creator A5018055017 @default.
• W3090717270 creator A5020891630 @default.
• W3090717270 creator A5021608465 @default.
• W3090717270 creator A5023307172 @default.
• W3090717270 creator A5024087236 @default.
• W3090717270 creator A5027418526 @default.
• W3090717270 creator A5028568303 @default.
• W3090717270 creator A5029582681 @default.
• W3090717270 creator A5030740162 @default.
• W3090717270 creator A5031713882 @default.
• W3090717270 creator A5032921214 @default.
• W3090717270 creator A5036920010 @default.
• W3090717270 creator A5041183761 @default.
• W3090717270 creator A5041415448 @default.
• W3090717270 creator A5043379810 @default.
• W3090717270 creator A5049550312 @default.
• W3090717270 creator A5058157547 @default.
• W3090717270 creator A5059355135 @default.
• W3090717270 creator A5059396155 @default.
• W3090717270 creator A5063989107 @default.
• W3090717270 creator A5064664004 @default.
• W3090717270 creator A5074893397 @default.
• W3090717270 creator A5076849098 @default.
• W3090717270 creator A5077489159 @default.
• W3090717270 creator A5077598738 @default.
• W3090717270 creator A5079489250 @default.
• W3090717270 creator A5081978275 @default.
• W3090717270 creator A5084189639 @default.
• W3090717270 creator A5085482528 @default.
• W3090717270 creator A5088431604 @default.
• W3090717270 date "2020-12-17" @default.
• W3090717270 modified "2023-10-18" @default.
• W3090717270 title "Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults" @default.
• W3090717270 cites W2030896204 @default.
• W3090717270 cites W2135926866 @default.
• W3090717270 cites W2146890931 @default.
• W3090717270 cites W2155668593 @default.
• W3090717270 cites W2158112090 @default.
• W3090717270 cites W2160358721 @default.
• W3090717270 cites W2317048712 @default.
• W3090717270 cites W2750464792 @default.
• W3090717270 cites W2752754315 @default.
• W3090717270 cites W2903322118 @default.
• W3090717270 cites W2944588091 @default.
• W3090717270 cites W2963951165 @default.
• W3090717270 cites W3003217347 @default.
• W3090717270 cites W3012310845 @default.
• W3090717270 cites W3015751519 @default.
• W3090717270 cites W3026558549 @default.
• W3090717270 cites W3030748957 @default.
• W3090717270 cites W3034816694 @default.
• W3090717270 cites W3036931136 @default.
• W3090717270 cites W3039901154 @default.
• W3090717270 cites W3043722389 @default.
• W3090717270 cites W3046061621 @default.
• W3090717270 cites W3047091198 @default.
• W3090717270 cites W3047144258 @default.
• W3090717270 doi "https://doi.org/10.1056/nejmoa2028436" @default.
• W3090717270 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7556339" @default.
• W3090717270 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32991794" @default.
• W3090717270 hasPublicationYear "2020" @default.
• W3090717270 type Work @default.
• W3090717270 sameAs 3090717270 @default.
• W3090717270 citedByCount "1127" @default.
• W3090717270 countsByYear W30907172702020 @default.
• W3090717270 countsByYear W30907172702021 @default.
• W3090717270 countsByYear W30907172702022 @default.
• W3090717270 countsByYear W30907172702023 @default.
• W3090717270 crossrefType "journal-article" @default.
• W3090717270 hasAuthorship W3090717270A5000950209 @default.
• W3090717270 hasAuthorship W3090717270A5004205181 @default.
• W3090717270 hasAuthorship W3090717270A5005833714 @default.
• W3090717270 hasAuthorship W3090717270A5005860294 @default.
• W3090717270 hasAuthorship W3090717270A5013550134 @default.
• W3090717270 hasAuthorship W3090717270A5014451298 @default.
• W3090717270 hasAuthorship W3090717270A5017501496 @default.
• W3090717270 hasAuthorship W3090717270A5018055017 @default.
• W3090717270 hasAuthorship W3090717270A5020891630 @default.
• W3090717270 hasAuthorship W3090717270A5021608465 @default.
• W3090717270 hasAuthorship W3090717270A5023307172 @default.
• W3090717270 hasAuthorship W3090717270A5024087236 @default.
• W3090717270 hasAuthorship W3090717270A5027418526 @default.
• W3090717270 hasAuthorship W3090717270A5028568303 @default.
• W3090717270 hasAuthorship W3090717270A5029582681 @default.
• W3090717270 hasAuthorship W3090717270A5030740162 @default.
• W3090717270 hasAuthorship W3090717270A5031713882 @default.
• W3090717270 hasAuthorship W3090717270A5032921214 @default.
• W3090717270 hasAuthorship W3090717270A5036920010 @default.
• W3090717270 hasAuthorship W3090717270A5041183761 @default.

• next